CHOKSI LABORATORIES LTD.

Choksi Laboratories Ltd has announced the closure of its trading window effective October 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and related circulars. The window will remain shut for all designated persons, their immediate relatives, and connected persons until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ended September 30, 2026. The company has also confirmed compliance with recent SEBI circulars regarding the freezing of PAN at the security level. The exact date for the board meeting to approve these financial results will be communicated later.

Choksi Laboratories Ltd has announced its 1st Extra-Ordinary General Meeting (EOGM) for the Financial Year 2026-27. The meeting is scheduled for Saturday, October 17, 2026, at 12:30 PM IST, and will be conducted via Video Conferencing/Other Audio-Visual Means. Key details include a cut-off date of October 10, 2026, for voting eligibility and a remote e-voting period from October 14 to October 16, 2026. The primary business to be transacted is the consideration and approval of the issue and allotment of convertible warrants on a preferential basis to the promoter and promoter group. The notice of the EOGM, along with an explanatory statement, has been provided and is also available on the company's website.

Choksi Laboratories Ltd's Board of Directors approved the preferential issuance of up to 350,000 convertible warrants to the promoter and promoter group. Each warrant is priced at ₹177, aggregating to ₹6.195 crore. This issuance is subject to shareholder approval at an Extra-Ordinary General Meeting (EGM) scheduled for October 17, 2026. An initial payment of 25% of the warrant price is required at the time of subscription and allotment.

Choksi Laboratories Ltd's Board of Directors approved the issuance and allotment of up to 3,50,000 fully convertible warrants on a preferential basis to the Promoter and Promoter Group. Each warrant is priced at ₹177, aggregating to a maximum of ₹6,19,50,000. This preferential issue is subject to shareholder approval at an Extra Ordinary General Meeting (EGM) scheduled for Saturday, October 17, 2026, via Video Conferencing or Other Audio-Visual Means. The board also approved the notice for the EGM and appointed CS Surabhi Agrawal as Scrutinizer for the e-voting process. An amount equivalent to 25% of the warrant issue price will be payable at subscription.

Choksi Laboratories Ltd has announced a Board of Directors meeting scheduled for September 19, 2026. The primary agenda item is to consider and approve a proposal for raising funds through the issuance of equity shares, equity-linked securities, or convertible instruments like warrants. This fund-raising activity will be conducted via preferential issue or other permissible modes, in compliance with the Companies Act, 2013, SEBI regulations, and other applicable laws. The proposal is subject to shareholder and necessary regulatory approvals. The meeting will also address any other business with the Chairman's permission and director consent.

Choksi Laboratories Ltd has informed the stock exchanges about the dispatch of letters to shareholders whose email addresses are not registered. These letters provide a web-link to access the Annual Report for FY 2025-26 and the notice for the upcoming 33rd Annual General Meeting (AGM). The AGM is scheduled for September 18, 2026, and will be held via Video Conferencing. Shareholders can access the report and notice online or request a physical copy. The company also provided contact details for updating shareholder information and mentioned the availability of documents on stock exchange websites.

Choksi Laboratories Ltd has submitted its 33rd Annual Report for the Financial Year 2025-26, along with the Notice of the 33rd Annual General Meeting (AGM). The AGM is scheduled for Friday, September 18, 2026, at 12:30 PM IST, to be conducted via Video Conferencing (VC)/Other Audio Visual Means (OAVM). The company is offering remote e-voting and e-voting during the AGM to all shareholders. Central Depository Services (India) Ltd. has been engaged as the authorized agency for this purpose. The report highlights the company's focus on strengthening its position in analytical testing services, investments in advanced instruments and digital technologies, and commitment to sustainable business practices. Key sectors served include pharmaceuticals, food & beverages, water, and environmental monitoring.

Choksi Laboratories Ltd has announced its 33rd Annual General Meeting (AGM) will be held on September 18, 2026, at 12:30 PM IST. The meeting will be conducted via Video Conference/Other Audio-Visual Means, adhering to SEBI and MCA circulars. The Annual Report, including the AGM notice for the financial year ended March 31, 2026, is being sent electronically to registered members. Shareholders without registered email addresses will receive a web-link to access the report. Key agenda items include approving audited financial results for FY26, re-appointing a director retiring by rotation, and re-appointing Ms. Himika Choksi as Whole-Time Director for another five years.

Choksi Laboratories Ltd has announced that the United States Food & Drug Administration (USFDA) conducted an inspection of its central laboratory in Indore from August 17 to August 20, 2026. Following the inspection, the company received four observations. Choksi Laboratories is committed to addressing these observations comprehensively and will submit its response to the USFDA within the stipulated timeframe. The company reaffirms its dedication to complying with USFDA regulations and maintaining high standards of quality and regulatory compliance.

Choksi Laboratories Ltd announced the reappointment of Ms. Himika Choksi as Whole Time Director for a further period of five years, effective April 1, 2027. This decision was made by the Board of Directors on August 13, 2025, and is subject to shareholder approval at the upcoming Annual General Meeting. Ms. Choksi, who is a promoter and has 25 years of experience in Quality Assurance and Control, will serve until March 31, 2032. She is related to other directors, including the Managing Director and two other Whole Time Directors.